Acyclovir Capsules
» Acyclovir Capsules contain not less than 93.0 percent and not more than 107.0 percent of the labeled amount of acyclovir (C8H11N5O3).
Packaging and storage— Preserve in tight containers. Store between 15 and 25. Protect from light and moisture.
Identification— The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Uniformity of dosage units 905: meet the requirements for Content Uniformity.
Dissolution 711
Medium: 0.1 N hydrochloric acid; 900 mL.
Apparatus 1: 100 rpm.
Time: 45 minutes.
Procedure— Determine the amount of C8H11N5O3 dissolved from UV absorption at the wavelength of maximum absorbance at about 254 nm on filtered portions of the solution under test, suitably diluted with 0.1 N hydrochloric acid in comparison with a Standard solution having a known concentration of USP Acyclovir RS in the same Medium.
Tolerances— Not less than 75% (Q) of the labeled amount of C8H11N5O3 is dissolved in 45 minutes.
Related compounds—
Mobile phase and Chromatographic system— Proceed as directed in the Assay.
Test solution— Use the Assay preparation.
Procedure— Inject a volume (about 20 µL) of the Test solution into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the percentage of each impurity in the portion of Capsules taken by the formula:
100(ri / rs)
in which ri is the peak response for each impurity; and rs is the sum of the responses for all of the peaks: not more than 2.0% of guanine is found; and not more than 0.5% of any individual impurity is found.
Assay—
Mobile phase— Prepare a filtered and degassed solution of 0.02 M acetic acid. Make adjustments if necessary (see System Suitability under Chromatography 621).
System suitability preparation 1— Dissolve accurately weighed quantities of USP Acyclovir RS and guanine in 0.1 N sodium hydroxide, and dilute quantitatively, and stepwise if necessary, with water to obtain a solution having a known concentration of about 0.1 mg of each per mL.
System suitability preparation 2— Dissolve an accurately weighed quantity of guanine in 0.1 N sodium hydroxide, and dilute quantitatively, and stepwise if necessary, with water to obtain a solution having a known concentration of about 2.0 µg per mL.
Standard preparation— Dissolve an accurately weighed quantity of USP Acyclovir RS in 0.1 N sodium hydroxide, and dilute quantitatively, and stepwise if necessary, with water to obtain a solution having a known concentration of about 0.1 mg per mL.
Assay preparation— Remove, as completely as possible, the contents of not fewer than 10 Capsules. Transfer an accurately weighed portion of the powder, equivalent to about 10 mg of acyclovir, to a 100-mL volumetric flask, dissolve in 10 mL of 0.1 N sodium hydroxide, dilute with water to volume, mix, and filter.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 254-nm detector and a 4.2-mm × 25-cm column that contains packing L1. The flow rate is about 1.5 mL per minute. Chromatograph System suitability preparation 1, and record the peak responses for acyclovir as directed for Procedure: the relative retention times are about 0.6 for guanine and 1.0 for acyclovir; the resolution, R, between guanine and acyclovir is not less than 2.0; and the relative standard deviation for replicate injections of acyclovir is not more than 2.0%. Chromatograph System suitability preparation 2, and record the peak responses as directed for Procedure: the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the quantity, in mg, of acyclovir (C8H11N5O3) in the portion of Capsules taken by the formula:
100C(rU / rS)
in which C is the concentration, in mg per mL, of USP Acyclovir RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Behnam Davani, Ph.D., M.B.A.
Senior Scientist
1-301-816-8394
(MDAA05) Monograph Development-Antivirals and Antimicrobials
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org
711 Margareth R.C. Marques, Ph.D.
Senior Scientist
1-301-816-8106
(BPC05) Biopharmaceutics05
USP32–NF27 Page 1428
Pharmacopeial Forum: Volume No. 30(2) Page 432
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.